SCHEMBL16098656

SCHEMBL16098656

O=CCCn1c2ccccc2c2ccccc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 3/20 0.53
FABP5 Q01469 3/20 0.53
FABP3 P05413 1/20 0.53
CYP1A2 P05177 1/20 0.52
CYP2C19 P33261 1/20 0.52
KDM4E B2RXH2 2/20 0.52
HDAC6 Q9UBN7 4/20 0.49
PTGER4 P35408 1/20 0.46
CYP19A1 P11511 1/20 0.45
HDAC1 Q13547 3/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
BACE1 P56817 2/20 0.44
DAO P14920 1/20 0.44
MAOA P21397 2/20 0.43
MAOB P27338 2/20 0.43
PGR P06401 1/20 0.43
RORA P35398 1/20 0.43
RORC P51449 1/20 0.43
RORB Q92753 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28472251 0.88 FABP4 (0.56) FABP4FABP5FABP3CYP1A2CYP2C19
SCHEMBL27098822 0.85 MAOA (0.68) FABP4FABP5FABP3CYP1A2CYP2C19
SCHEMBL28679845 0.81 FABP4 (0.60) FABP4FABP5FABP3CYP1A2CYP2C19
SCHEMBL9905075 0.79 PSEN1 (0.50) FABP4FABP5HDAC6HDAC1MAOA
SCHEMBL9768532 0.79 CYP1A2 (0.70) FABP4FABP5FABP3CYP1A2CYP2C19
SCHEMBL3561822 0.79 CYP1A2 (0.52) FABP4FABP5FABP3CYP1A2CYP2C19
SCHEMBL30800895 0.79 CYP1A2 (0.52) FABP4FABP5FABP3CYP1A2CYP2C19
SCHEMBL13456337 0.78 CYP1A2 (0.56) FABP4FABP5FABP3CYP1A2CYP2C19
SCHEMBL1401150 0.77 SLC6A4 (0.58) FABP4FABP5HDAC6HDAC1MAOA
SCHEMBL4552481 0.75 FABP4 (0.68) FABP4FABP5FABP3CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110003172-A The amides containing carbazole, carbamates and ureas as cryptochrome regulator 同步制药公司 2019-07-12 CN disclosed
CN-109627205-A The preparation method and applications of a kind of carbazyl Isopropanolamine derivatives 贵州大学 2019-04-16 CN disclosed
CN-106458891-B Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators 同步制药公司 2019-04-09 CN disclosed
US-20160024083-A1 COMPOUNDS AND METHODS FOR TREATING CANCERS HEALTH RESEARCH, INC. (US) 2016-01-28 US disclosed
US-20160024083-A1 COMPOUNDS AND METHODS FOR TREATING CANCERS HEALTH RESEARCH, INC. (US) 2016-01-28 US disclosed
US-20160024083-A1 COMPOUNDS AND METHODS FOR TREATING CANCERS HEALTH RESEARCH, INC. (US) 2016-01-28 US disclosed
WO-2014153043-A1 COMPOUNDS AND METHODS FOR TREATING CANCERS HEALTH RESEARCH, INC. (US) 2014-09-25 WO disclosed
WO-2014153043-A1 COMPOUNDS AND METHODS FOR TREATING CANCERS HEALTH RESEARCH, INC. (US) 2014-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024083-A1 COMPOUNDS AND METHODS FOR TREATING CANCERS AR, KLK3, BRDT FABP4 3191/4885FABP5 2398/4885FABP3 3971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.